

Title (en)
TREATMENT OF ESOPHAGEAL CANCER

Publication
EP 0572563 A4 19931229 (EN)

Application
EP 92908199 A 19920207

Priority
US 65893691 A 19910221

Abstract (en)
[origin: WO9214470A1] A method of treating esophageal cancer in a human afflicted therewith which comprises administering to such human an effective amount of a compound of the water soluble camptothecin analog class.

IPC 1-7
A61K 31/535

IPC 8 full level
A61K 31/47 (2006.01); **A61K 31/495** (2006.01); **A61K 31/535** (2006.01); **A61P 35/00** (2006.01); **C07D 491/22** (2006.01)

CPC (source: EP KR)
A61K 31/47 (2013.01 - EP); **A61K 31/495** (2013.01 - EP); **A61K 31/535** (2013.01 - EP KR); **A61P 35/00** (2017.12 - EP)

Citation (search report)

- [DX] EP 0321122 A2 19890621 - SMITHKLINE BECKMAN CORP [US]
- [A] C.G. MOERTEL ET AL: "Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer.", CANCER CHEMOTHER REP., vol. 56, no. 1, 1972, pages 95 - 101
- [A] M.R. MATTERN ET AL: "Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor SKF 104864.", PROC. AM. ASSOC. CANCER RES. ANNU. MEET., vol. 31, 1990, pages 436
- [A] Y. OHE ET AL: "Pharmacokinetics with a 5-day continuous infusion of a camptothecin derivative, CPT-11.", PROC. ANNU. MEET. AM. SOC. CLIN. ONCOL., vol. 10, 1991, pages 117
- See references of WO 9214470A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DOCDB simple family (publication)
WO 9214470 A1 19920903; AU 1540692 A 19920915; AU 664172 B2 19951109; CA 2104449 A1 19920822; EP 0572563 A1 19931208; EP 0572563 A4 19931229; JP H06505487 A 19940623; KR 930702985 A 19931129; MX 9200725 A 19920901; PT 100154 A 19930531

DOCDB simple family (application)
US 9201029 W 19920207; AU 1540692 A 19920207; CA 2104449 A 19920207; EP 92908199 A 19920207; JP 50780792 A 19920207; KR 930702492 A 19930820; MX 9200725 A 19920221; PT 10015492 A 19920221